-Review the staging and treatment of esophageal and GEJ cancer
-Discuss the population, methods, and results of the Checkmate 577 trial
-Understand the mechanism of action of nivolumab and the PD1 pathway
-Discuss the implications of the Checkmate 577 trial in clinical practice and areas of future research
Kelly Daus MD, Megan Lenihan MD, Peter White MD, and Brian Louie MD
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742. PMID: 32266087; PMCID: PMC7136921.
Ad referenced in episode: A team at the Brooke Army Medical Center is working to better define proficiency-based metrics for competency in commonly performed robotic general surgery procedures. If you are a general surgery resident or practicing surgeon who performs robotic assisted cholecystectomies or inguinal hernia repairs, reach out to the PI, Robert Laverty, MD, at firstname.lastname@example.org for more information on how you could be compensated $500 per video submitted of each (up to $1000 per surgeon).
Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
If you liked this episode, check out other thoracic surgery episodes here https://behindtheknife.org/podcast-category/cardiothoracic/